FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis
CJ Edwards(University Hospital Southampton NHS Foundation Trust), CA Birbara(University of Massachusetts Chan Medical School), Jeffrey Crowley, Nikolay Delev(Bristol-Myers Squibb (Sweden)), Francisco J. Blanco(Complexo Hospitalario Universitario A Coruña), Lichen Teng(Harbin Medical University), Maria Paris(Amgen (United States)), M. McIlraith(Bristol-Myers Squibb (Switzerland))
Cited by 4
Related Papers
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
|Annals of the Rheumatic Diseases|2016|286
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis
|Arthritis & Rheumatology|2019|215
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis
|JAMA Dermatology|2023|148
Differential proteomic analysis of the secretome of Irpex lacteus and other white-rot fungi during wheat straw pretreatment
|Biotechnology for Biofuels|2013|106